<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01254825</url>
  </required_header>
  <id_info>
    <org_study_id>SM2-ME-10</org_study_id>
    <nct_id>NCT01254825</nct_id>
  </id_info>
  <brief_title>The Efficacy of Adductor-Canal-Block (ACB) in Patients After Knee Arthroscopy</brief_title>
  <official_title>The Efficacy of Adductor-Canal-Block (ACB) in Patients After Knee Arthroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Purpose of this study is to determine whether Adductor-Canal-Block (ACB) is superior to
      placebo when it comes to analgetic efficacy after Knee-Arthroscopy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain-Score (VAS) - patient standing</measure>
    <time_frame>2 hours postoperative</time_frame>
    <description>Pain-score messured on a Visual Analog Scale (VAS) 2 hours after adductor canal block. Patient standing. Intervention-group vs. placebo-group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain-score (VAS), patient at rest</measure>
    <time_frame>0,1,2,4,6,8,24 hours postoperative</time_frame>
    <description>ACB-group vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain-score (VAS), patient standing</measure>
    <time_frame>1,2,4,6,8,24 hours postoperative</time_frame>
    <description>ACB-group vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain-score (VAS), after 5 meters of walk</measure>
    <time_frame>2,4,6,8,24 hours postoperative</time_frame>
    <description>ACB-group vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Opioid-consumption</measure>
    <time_frame>0-24 hours postoperative</time_frame>
    <description>ACB-group vs. placebo-group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid-consumption, postoperative</measure>
    <time_frame>0-2, 2-4, 4-6, 6-8, 8-24 hours postoperative</time_frame>
    <description>i.v. morfin 0-2 hours postoperative tbl. morfin 2-24 hours postoperative ACB vs. placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Nausea and vomiting</measure>
    <time_frame>0-1, 1-2, 2-4, 4-6, 6-8, 8-24 hours postoperative</time_frame>
    <description>Rating-scale 0-3 ACB-group vs. placebo-group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative ondansetron consumption</measure>
    <time_frame>In-hospital</time_frame>
    <description>ACB-group vs. placebo-group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation</measure>
    <time_frame>0,1,2,4,6,8,24 hours postoperative</time_frame>
    <description>Rating-scale: 0-3 ACB-group vs. placebo-group</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Meniscus Lesion</condition>
  <condition>Pain (Knee)</condition>
  <condition>Diagnostic Knee Artroscopy</condition>
  <condition>Minor Knee Surgery</condition>
  <arm_group>
    <arm_group_label>Adductor-Canal-Block, Ropivacain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adductor-Canal-Block, 30 mL Ropivacain 7,5 mg/mL. Single dose. Ultrasound-guided application. 36 patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adductor-Canal-Block (ACB) - Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Adductor-Canal-Block, Placebo (30 mL Saline). Ultrasound-guided application. 36 patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adductor-Canal-Block, Ropivacain</intervention_name>
    <description>Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.</description>
    <arm_group_label>Adductor-Canal-Block, Ropivacain</arm_group_label>
    <other_name>Naropin (Ropivacain)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Adductor Canal Block, Placebo (saline)</intervention_name>
    <description>Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.</description>
    <arm_group_label>Adductor-Canal-Block (ACB) - Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-80 years

          -  Knee-arthroscopy

          -  Written consent

          -  ASA I-III

          -  BMI 19-35

        Exclusion Criteria:

          -  Unable to communicate in Danish

          -  Allergic reactions toward drugs used in the trial

          -  Pregnancy

          -  Abuse of alcohol/drugs

          -  Daily opioid intake

          -  Infection at injection site

          -  Can not be mobilised to 5 meters of walk; pre-surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Malene Espelund, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup University Hospital, Copenhagen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Anaesthesiology, Glostrup University Hospital</name>
      <address>
        <city>Glostrup</city>
        <state>Copenhagen</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 6, 2010</study_first_submitted>
  <study_first_submitted_qc>December 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2010</study_first_posted>
  <last_update_submitted>September 9, 2012</last_update_submitted>
  <last_update_submitted_qc>September 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Glostrup University Hospital, Copenhagen</investigator_affiliation>
    <investigator_full_name>Malene Espelund</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Adductor Canal Block (ACB)</keyword>
  <keyword>Diagnostic Knee Arthroscopy</keyword>
  <keyword>Saphenous nerve</keyword>
  <keyword>Pain</keyword>
  <keyword>Ultrasound block</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

